Search Results for:
-
Elan Looks East with 2 Deals as Royalty Revises Hostile Bid
They include a pegylated interferon-alpha-2b, in development for the bone marrow disorder polycythemia vera, and a dendritic cell therapy for treating glioblastoma, which its subsidiary Activartis Biotech GmbH, also of Vienna, is developing. (See BioWorld Today, April 10, 2003.) Market Diversification Newbridge, based in Dubai, in the United Arab Emirates, is an earlier-stage ventureBio Perspectives | Wednesday, May 22, 2013 -
GSK's Academic Competition Aims to Accelerate Innovation
Since running a screen is the first step for many projects, we thought if we break it down, the early stage of a collaboration will move more quickly because itBy Nuala Moran | BioWorld Today | Wednesday, May 22, 2013 -
Pfizer Phase III Failure Hints at ADC Shortcomings
Early stage ADCs using less stable linking technologies are inherently imprecise and less efficient, translating into smaller payloads of the targeted agent actually reaching a tumor cell, agreed Trevor Hallam, chief scientific officer of San Francisco-based Sutro Biopharma Inc., another developer of next-generation ADCs. (See BioWorld Today, Dec. 19, 2012.) Site-specific conjugations result in more precise targeting and more homogenous products that are easier for regulators to reviewBy Marie Powers | BioWorld Today | Wednesday, May 22, 2013 -
Novo Snags Xellia for $700M; Continues Investment Strategy
That represents a shift from its original strategy, involving earlier-stage companies approaching commercializationBy Cormac Sheridan | BioWorld Today | Wednesday, May 22, 2013 -
Novo Snags Xellia for $700M; Continues Investment Strategy
That represents a shift from its original strategy, involving earlier-stage companies approaching commercializationBy Cormac Sheridan | BioWorld International | Wednesday, May 22, 2013 -
MS Ventures Expands, Moves Early Firms Along Dual Track
LONDON – Merck Serono is enlarging its venture fund from €40 million to €100 million (US$51 million to $128 million) – increasing its capacity to invest in early stage companies, technologies and products that can be shaped up for the company's internal pipeline...And although other pharma companies have established VC funds with a similar aim of accessing innovation, Bulthuis said the overall shortage of funding for early stage companies means the competition for assets is not intenseBy Nuala Moran | BioWorld International | Wednesday, May 22, 2013 -
Elan Looks East with 2 Deals as Royalty Revises Hostile Bid
They include a pegylated interferon-alpha-2b, in development for the bone marrow disorder polycythemia vera, and a dendritic cell therapy for treating glioblastoma, which its subsidiary Activartis Biotech GmbH, also of Vienna, is developing. (See BioWorld Today, April 10, 2003.) Market Diversification Newbridge, based in Dubai, in the United Arab Emirates, is an earlier-stage ventureBy Cormac Sheridan | BioWorld International | Wednesday, May 22, 2013 -
GSK's Academic Competition Aims to Accelerate Innovation
Since running a screen is the first step for many projects, we thought if we break it down, the early stage of a collaboration will move more quickly because itBy Nuala Moran | BioWorld International | Wednesday, May 22, 2013 -
Elan Looks East with 2 Deals as Royalty Revises Hostile Bid
They include a pegylated interferon-alpha-2b, in development for the bone marrow disorder polycythemia vera, and a dendritic cell therapy for treating glioblastoma, which its subsidiary Activartis Biotech GmbH, also of Vienna, is developing. (See BioWorld Today, April 10, 2003.) Market Diversification Newbridge, based in Dubai, in the United Arab Emirates, is an earlier stage ventureBy Cormac Sheridan | BioWorld Today | Tuesday, May 21, 2013 -
Xenoport Drops Spasticity Drug, Reboots Horizant
In short, the company concluded the study was appropriately designed and executed, leading Xenoport with little choice than to terminate the AP program as quickly as possible to conserve cash and shift resources to Horizant and the company's early stage fumarate candidate, XP23829...Xenoport Places Bets in Early Stage BG-12 Prodrug Horizant badly needs a jump startBy Marie Powers | BioWorld Today | Tuesday, May 21, 2013 -
MS Ventures Expands, Moves Early Firms Along Dual Track
LONDON – Merck Serono is enlarging its venture fund from €40 million to €100 million (US$51 million to $128 million) – increasing its capacity to invest in early stage companies, technologies and products that can be shaped up for the company's internal pipeline...And although other pharma companies have established VC funds with a similar aim of accessing innovation, Bulthuis said the overall shortage of funding for early stage companies means the competition for assets is not intenseBy Nuala Moran | BioWorld Today | Tuesday, May 21, 2013 -
Biotech Collaborations Between Pharmaceutical & Miscellaneous Companies: April 1 - May 16, 2013
early stage life science companies Avalon will provide up to $30M, while GSK will contribute seed funding, research and development support and success-based preclinical and clinical milestone payments up to a total of $465M for the 10 companies 4/24/13 Merck & CoBioWorld Insight | Monday, May 20, 2013 -
Collaborations Between Biotech And Pharmaceutical Companies: April 1 - May 16, 2013
Inc. (Whitehouse Station, N.J.) ND Hawaii acquired ownership of a patent family to West Nile virus vaccine technology, together with a nonexclusive license to recombinant protein expression technology Financial terms were not disclosed 4/12/13 Horizon Discovery Ltd. (Cambridge, UK) AstraZeneca plc (London) $75 Deal that provides services and products to applying Horizon Discovery's genome-editing technology to uncover novel targets AstraZeneca gets access to an early stage, first-in-class kinaseBioWorld Insight | Monday, May 20, 2013 -
Embryonic Stem Cells: Individual Medicine - But With 2 Individuals
But the more common view is that an early stage embryo is an early human life that is not yet a person, and is not the moral equivalent of a babyBy Anette Breindl | BioWorld Insight | Monday, May 20, 2013 -
Pharma: Other News To Note
Bayer HealthCare Pharmaceuticals Inc., of Wayne, N.J., signed a three-year agreement with the California Institute for Quantitative Biosciences (QB3) to evaluate life sciences start-up companies with the goal of advancing early stage technologies and therapeuticsBioWorld Today | Friday, May 17, 2013 -
Algeta's Xofigo Wins FDA Nod Ahead of Schedule
on the strategy for expanding Radium-223 development, importantly further studies in metastatic castrate-resistant prostate cancer (mCRPC), potentially in combination with oral Zytiga/Xtandi and/or in earlier stage patients, but also a possible Phase II trial in metastatic breast cancerBy Catherine Shaffer | BioWorld Today | Thursday, May 16, 2013 -
Astellas Axes OSI, Perseid Units, Cuts Jobs in Japan
sales force, a pipeline of small molecules and early stage discovery capabilities...and early stage programs for diabetes and obesity. (See BioWorld Today, May 18, 2010.) The following year, Astellas snagged Perseid for $76 million by exercising an option to buy out the equity interest of a joint venture partner, Maxygen IncBy Marie Powers | BioWorld Today | Wednesday, May 15, 2013 -
Pharma: Other News To Note
Actavis Inc., of Parsippany, N.J., on Friday confirmed that it entered early stage discussions with Warner Chilcott plc, of Dublin, Ireland, regarding a potential combination of the two companiesBioWorld Today | Monday, May 13, 2013 -
Other News To Note
The deal is the first for Shire's strategic alliance with Atlas Venture, which identifies investments for early stage venture creation around rare genetic diseasesBioWorld Today | Thursday, May 9, 2013 -
Expanding Redx Inks Cancer Alliance with Pharmascience
has unveiled a shift in strategy away from a sole focus on internally generated compounds, with the in-licensing of an early stage oncology program from Canadian biotech Pharmascience Inc...Most early stage companies don't have the skills to take things forward to something of interest to pharma," Murray saidBy Nuala Moran | BioWorld International | Wednesday, May 8, 2013
Category
Current Filters
- xearly stage
Related Keywords
Categories
- x BioWorld Today (2903)
- x BioWorld International (822)
- x BioWorld Insight (440)
- x Bio Perspectives (176)
- x State of the Industry Report (78)
- x BioWorld Genomics Review (24)
- x BioWorld Snapshots (21)
- x Biotech Innovations (19)
- x Top 25 Drug Report (11)
- x Market-Leading Biotech Drugs (3)
- x BioWorld Phase III Report (1)
- x RNAi Report (1)
- x MDD (1)
- x Recorded (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.